Author

Wenqi Li

First Affiliated Hospital of Guangzhou Medical UniversityORCID 0000-0002-3034-0992Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:graph neural network· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Jinsai ShangiD· 2 shared Miru Tang· 2 shared Yongzhi LuiD· 2 shared Anqi ZhouiD· 1 shared Bao Xue· 1 shared Cong MaiD· 1 shared Guihua Zhang· 1 shared Hongming CheniD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

Jinsai ShangORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

FXR-mediated recruitment of PPP1CB suppresses SMAD2/3 phosphorylation to mitigate pulmonary fibrosis

Wenqi Li, Qiong Wu, Yongzhi Lu, Xiaoqin Li, Lei Miao, Xia Y, Xianjie Qiu, Miru Tang, Z Y Li, Yang Peng, Wenxiang Hu, Wei Kevin Zhang, Jie Zheng, Cong Ma, Jinsai Shang

This study identifies FXR as a suppressor of pulmonary fibrosis by interacting with PPP1CB to reduce SMAD2/3 phosphorylation, showing therapeutic potential with TERN101.

bioRxiv · Jul 24, 2026 · PreprintCell Biology

Discovery of resistance-resilient quinoline papain-like protease inhibitors through topology-constrained molecular generative design

Yongzhi Lu, Ting Ran, Qi Yang, Guihua Zhang, Jiayi Chen, Peiqi Zhou, Wenqi Li, Minyuan Xu, Jielin Tang, Minxian Dai, Jinpeng Zhong, Hua Chen, Pan He, Anqi Zhou, Bao Xue, , Jinsai Shang

This paper discovers a novel quinoline-based PLpro inhibitor, GZNL-2016, that remains effective against drug-resistant SARS-CoV-2 variants like Omicron BA.5 and XBB.1.

bioRxiv · Sep 7, 2024 · PreprintMicrobiology